-
Earnings Scheduled For August 25
Thursday, August 25, 2011 - 4:00am | 586Krispy Kreme Doughnuts Inc (NYSE: KKD) is expected to report its Q2 EPS at $0.06 on revenue of $92.26 million. Hormel Foods Corporation (NYSE: HRL) is estimated to report its Q3 EPS at $0.35 on revenue of $1.87 billion. Shoe Carnival Inc (NASDAQ: SCVL) is projected to report its Q2 EPS at $0.30...
-
Notable Put Options Activity in Hologic
Wednesday, August 24, 2011 - 2:57pm | 86Shares of Hologic (NASDAQ: HOLX) are lower on the session by 0.50%, currently trading at $16.39. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are focusing on puts today. A short while ago the September...
-
UPDATE: Oppenheimer Lowers PT on Medtronic from $48 to $42
Wednesday, August 24, 2011 - 9:22am | 77Oppenheimer has published a research report on Medtronic (NYSE: MDT) lowering the price target. In the report, Oppenheimer wrote, "On MDT's F1Q call, mgmt noted continued ICD/Spine pressures, reiterated FY12 guidance on solid performance from its remaining business lines/cost savings, and...
-
Physio-Control Introduces New Basic Life Support 12-Lead ECG Solution
Wednesday, August 24, 2011 - 9:18am | 59Physio-Control, Inc., a global leader in emergency medical solutions and wholly‐owned subsidiary of Medtronic, Inc., (NYSE: MDT), today announced commercial availability of the ReadyLink 12-Lead ECG device, a new, U.S. Food and Drug Administration cleared solution designed to improve care for heart...
-
EDAP Partnership Wins EUR 2.4 Million Grant for Development of Innovative Imaging Solution for Focal Treatment of Prostate Cancer
Wednesday, August 24, 2011 - 8:32am | 99EDAP TMS SA (Nasdaq: EDAP) announced today that its development partnership has been awarded a EUR 2.4 million grant for further development of Ablatherm-HIFU technology to incorporate improved imaging and diagnostic techniques in line with the focal therapy approach for treating localized prostate...
-
UPDATE: Jefferies Lowers PT on Medtronic from $43 to $37
Wednesday, August 24, 2011 - 8:15am | 107Jefferies has published a research report on Medtronic (NYSE: MDT) lowering the price target. In the report, Jefferies wrote, "With the majority of Medtronic's end markets challenged by volume, pricing and competitive issues and with the ongoing evolution of healthcare on a global basis pointing...
-
Benzinga's Top Downgrades
Wednesday, August 24, 2011 - 7:49am | 129Morgan Keegan downgraded Abbott Laboratories (NYSE: ABT) from “outperform” to “market perform.” ABT's shares closed at $50.51 yesterday. Abbott Laboratories' trailing-twelve-month ROA is 8.03%. Pacific Sunwear of California Inc (NASDAQ: PSUN) was downgraded by Oppenheimer from "outperform" to "...
-
Benzinga's Top Upgrades
Wednesday, August 24, 2011 - 7:42am | 125Analysts at Morgan Keegan upgraded AtriCure Inc (NASDAQ: ATRC) from “market perform” to “outperform.” ATRC's shares closed at $10.82 yesterday. AtriCure's trailing-twelve-month revenue is $63.28 million. Analysts at Benchmark Company upgraded Tesoro Corporation (NYSE: TSO) from “sell” to “buy.”...
-
J.P. Morgan Maintains Neutral on Medtronic
Wednesday, August 24, 2011 - 7:41am | 137J.P. Morgan is out with its report today on Medtronic (NYSE: MDT), maintaining Neutral. In its report, J.P. Morgan writes, "Medtronic reported largely in-line 1Q results Tuesday morning. Revenues of $4.049B grew 7.3% reported (+2.4% cc; +1.1% organic) and came in $70M above consensus and $15M...
-
Morgan Stanley Checks In With Medtronic
Wednesday, August 24, 2011 - 7:14am | 87Morgan Stanley has published a research report on Medtronic (NYSE: MDT). In the report, Morgan Stanley wrote, "Expectations were low into the F1Q12 quarter, and given relatively in line results, achievable guidance (although less conservative than management thought), and comments from new CEO...
-
Deutsche Bank Maintains Views on Medtronic
Wednesday, August 24, 2011 - 7:08am | 97Deutsche Bank has published a research report on Medtronic (NYSE: MDT), maintaining their current position. In the report, Deutsche Bank wrote, "We are not disillusioned, nor do we think the new CEO is, about the enormity of the task ahead. MDT has struggled for a decade; given its sheer size it...
-
Wunderlich Initiates Edwards Lifesciences At Hold, $75 PT
Wednesday, August 24, 2011 - 6:49am | 25Wunderlich Securities has initiated coverage on Edwards Lifesciences (NYSE: EW) with a Hold rating and $75 price target.
-
Jefferies Lowers PT On Medtronic To $37
Wednesday, August 24, 2011 - 6:41am | 26Jefferies & Company has lowered the price target on Medtronic (NYSE: MDT) from $43 to $37 and maintains its Hold rating.
-
Morgan Keegan Downgrades Boston Scientific To Market Perform, Lowers PT To $7
Wednesday, August 24, 2011 - 6:09am | 30Morgan Keegan has downgraded Boston Scientific Corporation (NYSE: BSX) from Outperform to Market Perform and has lowered the price target from $8 to $7.
-
Deutsche Bank Lowers PT On Medtronic To $43
Wednesday, August 24, 2011 - 6:01am | 26Deutsche Bank has lowered the price target on Medtronic (NYSE: MDT) from $45 to $43 and maintains its Buy rating.